Buckingham Capital Management Inc. Boosts Stake in Becton, Dickinson and Company (NYSE:BDX)

Buckingham Capital Management Inc. increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,895 shares of the medical instruments supplier’s stock after buying an additional 883 shares during the period. Buckingham Capital Management Inc.’s holdings in Becton, Dickinson and were worth $2,723,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Becton, Dickinson and by 8.5% in the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after purchasing an additional 1,353,780 shares in the last quarter. BlackRock Inc. increased its stake in Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after purchasing an additional 15,887,611 shares in the last quarter. State Street Corp increased its stake in Becton, Dickinson and by 3.5% in the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after purchasing an additional 342,873 shares in the last quarter. Northern Trust Corp increased its stake in Becton, Dickinson and by 4.0% in the second quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock valued at $549,028,000 after purchasing an additional 106,966 shares in the last quarter. Finally, Fiera Capital Corp increased its stake in Becton, Dickinson and by 7.1% in the second quarter. Fiera Capital Corp now owns 2,782,146 shares of the medical instruments supplier’s stock valued at $542,825,000 after purchasing an additional 183,372 shares in the last quarter. 88.46% of the stock is owned by institutional investors and hedge funds.

In other news, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the sale, the insider now owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Stephen Sichak sold 11,787 shares of the business’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the completion of the sale, the insider now directly owns 14,038 shares in the company, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company (NYSE BDX) traded down $7.41 during trading on Monday, reaching $218.92. 1,695,385 shares of the company traded hands, compared to its average volume of 1,321,107. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $229.68. The stock has a market capitalization of $51,598.33, a PE ratio of 23.85, a PEG ratio of 1.77 and a beta of 1.07. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The firm’s revenue for the quarter was down 2.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.12 earnings per share. equities analysts predict that Becton, Dickinson and Company will post 10.65 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be given a $0.75 dividend. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $3.00 annualized dividend and a yield of 1.37%. Becton, Dickinson and’s payout ratio is currently 62.80%.

A number of research analysts have recently issued reports on the stock. Barclays reiterated an “equal weight” rating and set a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price objective for the company in a report on Tuesday, October 31st. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. BidaskClub cut shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Sunday, August 6th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Becton, Dickinson and presently has an average rating of “Buy” and an average target price of $217.08.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/05/buckingham-capital-management-inc-has-2-72-million-holdings-in-becton-dickinson-and-company-bdx.html.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply